Clinical review 106: Amenorrheic bone loss

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 6, 1999, Pages 1775-1783

  Miller, Karen K ^a   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN;

AMENORRHEA; ANOREXIA NERVOSA; BONE ATROPHY; DISEASE ASSOCIATION; FEMALE; HORMONE DEFICIENCY; HUMAN; HYPERPROLACTINEMIA; OSTEOPENIA; OVARY DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0033305315     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.6.5688     Document Type: Review

References (156)

1. Epidemiology of secondary amenorrhea
2. Adult-onset amenorrhea: A study of 262 patients
3. Menopausal changes in bone remodeling
4. Evidence of estrogen receptors in normal human osteoblast-like cells
5. Estrogen receptors and human bone cells: Immunocytochemical studies
6. Functional estrogen receptors in osteoblastic cells demonstrated by transfection with a reporter gene containing an estrogen response element
7. Differential expression of estrogen receptors α and β mRNA during differentiation of human osteoblast SV-HFO cells
8. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis
9. Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis
10. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells
11. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion
12. Increased osteoclast development after estrogen loss: Mediation by interleukin-6
13. Effects of estrogen in vivo and in vitro on spontaneous interleukin-1 release by monocytes from postmenopausal women
14. 17 β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens
15. An interleukin 1 like factor stimulates bone resorption in vitro
16. Estrogen protection against bone resorbing effects of parathyroid hormone infusion
17. Hypogonadotropic disorders in men and women: Diagnosis and therapy with pulsatile gonadotropin-releasing hormone
18. Neuroendocrine aberrations in women with functional hypothalamic amenorrhea
19. Anorexia nervosa. Immaturity of the 24-hour luteinizing hormone secretory pattern
20. Decreased bone density in hyperprolactinemic women
21. Decreased spinal mineral content in amenorrheic women
22. Vertebral body bone mineral content in hyperprolactinemic women
23. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea
24. Effects of prolactin and estrogen deficiency in amenorrheic bone loss
25. Increase in bone mass after treatment of hyperprolactinemic amenorrhea
26. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea
27. Estradiol regulates the transcription of the prolactin gene
28. Prolactin synthesis in primary cultures of pituitary cells: Regulation by estradiol
29. Pregnancy and the hyperprolactinemic woman
30. The effect of estrogen therapy on pituitary tumor growth and bone density in amenorrheic women with hyperprolactinemia
31. Osteopenia in women with hypothalamic amenorrhea: A prospective study
32. Secondary amenorrhea in athletes
33. Menstrual dysfunction in distance runners
34. The female athlete triad: Disordered eating, amenorrhea, osteoporosis
35. Bone density at weight-bearing and nonweight-bearing sites in ballet dancers: The effects of exercise, hypogonadism, and body weight
36. Menstrual function and bone mass in elite women distance runners. Endocrine and metabolic features
37. High-impact exercise promotes bone gain in well-trained female athletes
38. Bone mineral content of amenorrheic and eumenorrheic athletes
39. Exercise-induced amenorrhea and bone density
40. Bone density at multiple skeletal sites in amenorrheic athletes
41. Lack of bone accretion and amenorrhea: Evidence for a relative osteopenia in weight-bearing bones
42. Scoliosis and fractures in young ballet dancers. Relation to delayed menarche and secondary amenorrhea
43. The female athlete triad
44. Female athlete triad risk for women
45. Menstrual cycles: Fatness as a determinant of minimum weight for height necessary for their maintenance or onset
46. Body composition, age, and femoral bone mass of young adult women
47. Determinants of total-body and regional bone mineral content and density in post-pubertal normal women
48. Measurements of bone mineral density by DXA total body absorptiometry in different skeletal sites in postmenopausal osteoporosis
49. Comparison of bone density in amenorrheic women due to athletics, weight loss, and premature menopause
50. Diet and bone status in amenorrheic women
51. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri- and postmenopausal women
52. Sex steroids and bone density in premenopausal and perimenopausal women
53. Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea
54. Hypercortisolism in patients with functional hypothalamic-amenorrhea
55. Bone mineral density in women with depression
56. Basophile adenomas
57. Steroid-induced fractures and bone loss in patients with asthma
58. Glucocorticoid-induced osteoporosis: Pathogenesis and management
59. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography
60. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients
61. Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis
62. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration
63. Malabsorption of calcium in corticosteroid-induced osteoporosis
64. Positive cotranscriptional regulation of intestinal calbindin-D28K gene expression by 1-25-dihydroxyvitamin D3 and glucocorticoids
65. The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels
66. Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS17/2.8 and OK cells
67. Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone
68. Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: Correlations with growth parameters
69. Vertebral bone density in children: Effect of puberty
70. Longitudinal monitoring of bone mass accumulation in healthy adolescents: Evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects
71. Contribution of trans-acting factor alleles to normal physiological variability: Vitamin D receptor gene polymorphisms and circulating osteocalcin
72. Prediction of bone density from vitamin D receptor alleles
73. Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent
74. Bone mineral density after resumption of menses in amenorrheic athletes
75. Exercise-associated amenorrhea, low bone density, and estrogen replacement therapy
76. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months
77. Spinal bone loss and ovulatory disturbances
78. The clinical course of osteoporosis in anorexia nervosa
79. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa
80. Decreased bone density in adolescent girls with anorexia nervosa
81. Osteoporosis in women with anorexia nervosa
82. Bone mineral density and anorexia nervosa in women
83. Osteopaenia of the lumbar spine and femoral neck in anorexia nervosa
84. Reversible bone loss in anorexia nervosa
85. Relationship of bone density to estradiol and cortisol in anorexia nervosa and bulimia
86. Skeletal and body-composition effects of anorexia nervosa
87. Reduced bone mineral in patients with eating disorders
88. Decreased bone formation and increased mineral dissolution during acute fasting in young women
89. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa
90. Osteoporosis in women with eating disorders: Comparison of physical parameters, exercise and menstrual status with SPA and DPA evaluation
91. Bone metabolism and osteopenia in eating disorders
92. Recovery from osteopenia in adolescent girls with anorexia nervosa
93. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa
94. Outcome of bone mineral density in anorexia nervosa patients 11.7 years after first admission
95. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin 'add-back' regimens for women with leiomyomata uteri
96. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism
97. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?
98. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial
99. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buse-relin in premenopausal women
100. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment
101. Add-back therapy in the treatment of endometriosis: The North American experience
102. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: The role of cyclic sodium etidronate and low-dose norethindrone 'add-back' therapy
103. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): A randomized controlled trial
104. The effects of 17 β-estradiol and progestagen on trabecular bone remodeling in oophorectomized dogs
105. Progesterone as a bone-trophic hormone
106. Spinal bone density in women using depot medroxyprogesterone contraception
107. Bone density in women receiving depot medroxyprogesterone acetate for contraception
108. Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women
109. Recovery of bone density in women who stop using depot medroxyprogesterone acetate
110. Spinal mineral loss in oopherectomized women
111. On some late effects of bilateral oophorectomy in the age range 15-30 years
112. Bone mineralization in women following successful treatment of Hodgkin's disease
113. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer
114. Reduction of bone mass in women after bone marrow transplantation
115. Ovarian function after autologous bone marrow transplantation
116. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer
117. Gonadal function following chemotherapy for Hodgkin's disease: A comparative study of MVPP and a seven-drug hybrid regimen
118. Risk for developing osteoporosis in untreated premature menopause
119. Hypergonadotropic hypogonadic amenorrhea (World Health Organization III) and osteoporosis
120. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation
121. The impact of long term estrogen support after hysterectomy. A report of 1016 cases
122. Effects of natural menopause, hysterectomy, and oophorectomy on lumbar spine and femoral neck bone densities
123. Metabolic and hormonal effects of 25-mg and 50-mg 17β-estradial implants in surgically menopausal women
124. Prevention of bone loss following oophorectomy in premenopausal women: A retrospective assessment of the effects of oophorectomy and a prospective controlled trial of the effects of mestranol therapy
125. Premenopausal ovariectomy-related bone loss: A randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate
126. The effect of the antiestrogen tamoxifen on bone mineral density in normal late post-menopausal women
127. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
128. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
129. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group
130. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids
131. Effects of chronic prednisolone treatment on bone resorption and bone composition in intact and ovariectomized rats and in ovariectomized rats receiving β-estradiol
132. Bone loss in adults receiving alternate day glucocorticoid therapy. A comparison with daily therapy
133. Cyclosporin-A in vivo produces severe osteopenia in the rat: Effect of dose and duration of administration
134. Cyclosporin A in the oophorectomized rat: Unexpected severe bone resorption
135. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients
136. Osteopathien bei antiepileptishcer langzeittherapie (Vorlaufige mitteilung)
137. Osteomalacia with long-term anticonvulsant therapy in epilepsy
138. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on anti-epileptic drugs
139. Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro
140. Effects of diphenylhydantoin on synthesis of collagen and noncollagen protein in tissue culture
141. Osteoporotic fractures and the recurrence of thromboembolism during pregnany and the puerperium in 184 women undergoing thromboprophylaxis with heparin
142. Heparin effect on bone density
143. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study
144. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry
145. Alcohol dependence, smoking status, reproductive characteristics, and bone mineral density in premenopausal women
146. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis
147. Normal bone mineral density following cure of Cushing's syndrome
148. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome
149. Skeletal disease in primary hyperparathyroidism
150. Increased bone density after parathyroidectomy in primary hyperparathyroidism
151. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: Correlations with serum growth hormone responses to GH-releasing hormone, insulin-like gowth factor I, and IGF binding protein 3
152. Reduced bone mineral density in patients with adult onset growth hormone deficiency
153. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency
154. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency
155. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency